- Oil & Gas Exploration & Production
Friday, January 27, 2017
Jeld-Wen Holding (JELD) began trading on the NYSE on 27 Jan 2017
Description
JELD-WEN Holding, Inc. is a door and window manufacturer. The Company designs, produces and distributes a range of interior and exterior doors, wood, vinyl and aluminum windows, and related products for use in the new construction and repair and remodeling, of residential homes, and to an extent, non-residential buildings. It operates in three segments: North America, Europe and Australasia. It markets its products under the JELD-WEN brand, along with various regional brands, such as Swedoor and DANA in Europe and Corinthian, Stegbar and Trend in Australia. It operates over 110 manufacturing facilities in approximately 20 countries, located primarily in North America, Europe and Australia. It provides a portfolio of interior and exterior doors, windows, and related products, manufactured from a range of wood, metal, and composite materials. It manufactures wood, vinyl and aluminum windows in North America, wood and aluminum windows in Australia, and wood windows in the United Kingdom.
REV Group (REVG) began trading on the NYSE on 27 Jan 2017
The company was formerly known as Allied Specialty Vehicles, Inc. and changed its name to REV Group, Inc. in November 2015.
- Sector: Consumer Cyclical
- Industry: Recreational Vehicles
- Full Time Employees: 7,600
- Headquartered in Milwaukee, Wisconsin
- http://www.revgroup.com
Thursday, January 26, 2017
=AnaptysBio (ANAB) started trading on the Nasdaq on 26 Jan 2017
San Diego’s AnaptysBio raised $75 million Thursday in an initial public offering, making it the first U.S. biotech to do so this year.
The company sold 5 million shares at $15 apiece. Shares opened for trading Thursday under the ticker ANAB at $16 each.The offering includes a 30-day option to buy up to 750,000 additional shares.
AnaptysBio is developing anti-inflammatory drugs for conditions such as dermatitis, peanut allergy and a form of asthma. It has one drug in clinical trials, ANB020, that is being tested against these three conditions.
In addition, the company is preparing to start clinical trials on drugs for pustular psoriasis and various other inflammatory conditions, and is researching drugs for cancer.
The company has entered into partnerships to advance its drugs. It’s teamed with Celgene for inflammatory drugs and with Tesaro for cancer therapies.
Credit Suisse and Stifel are managing the offering. JMP Securities and Wedbush PacGrow are co-managers.
Wednesday, January 25, 2017
Great trade : ALLY +350% (2/17)
- Wed 1/25: 10, 15, 37
- 9, 10, 15, 22, 37, 59, 97
- bot ALLY Feb 17 $20 calls @ 0.35
- sold @ 1.60 on Wed 2/1
- profit $1.20 or 350% (stock +10%)
Trade | Details | 5,016 | vol 540 | 0.04 | 0.31 | 0.30 | 0.35 | 20.00 |
Wed 2/1 sold
Trade | Details | 5,077 | 0 | 0.00 | 1.20 | 1.60 | 1.70 | 20.00 |
Tuesday, January 24, 2017
Alibaba (BABA) reported earnings on Tue 24 Jan 2017 (b/o)
** charts before earnings **
** charts after earnings **
Alibaba beats by $0.17, beats on revs; raises FY17 rev growth :
- Reports Q3 (Dec) earnings of $1.30 per share, excluding non-recurring items, $0.17 better than the Capital IQ Consensus of $1.13; rev +54% to $7.67 bln vs. $7.34 bln consensus
- Revenue from core commerce increased 45% year-over-year to RMB46,576 million (US$6,708 million).
- Revenue from cloud computing increased 115% year-over-year to RMB1,764 million (US$254 million).
- Revenue from digital media and entertainment increased 273% year-over-year to RMB4,063 million (US$585 million).
- Revenue from innovation initiatives and others increased 61% year-over-year to RMB845 million (US$122 million).
- Mobile MAUs on our China retail marketplaces reached 493 million in December, an increase of 43 million over September, while annual active buyers on our China retail marketplaces reached 443 million, an increase of 4 million from the 12-month period ended in September.
- The number of paying customers of our cloud computing business grew to 765,000 from 651,000 in the previous quarter. Operating loss from cloud computing was RMB339 million (US$49 million) and adjusted EBITA loss was RMB92 million (US$13 million).
- Adj. EBITDA +41% to $3.9 bln.
- "The 11.11 Shopping Festival featured Alibaba at its best, integrating commerce, entertainment and social engagement, all happening globally at record scale. We are driving the age of 'New Retail,' which leverages big data and innovation to provide a seamless online and offline experience for nearly half a billion mobile monthly active users. This retail transformation will make it even easier and more efficient for brands and retailers to engage with these consumers anywhere, anytime."
- Co issues upside guidance for FY17, raises FY17 revs to +53% (from +48%) to $23.8 bln vs. $22.28 bln Capital IQ Consensus Estimate.
Tuesday, January 17, 2017
Adient (ADNT): 4-month performance
Alcobra Pharma (ADHD) reports that the Phase 3 clinical trial of MDX in adults with ADHD missed the primary endpoint
Alcobra Pharma reports that the Phase 3 clinical trial of MDX in adults with ADHD missed the primary endpoint :
In this trial, MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners' Adult ADHD Rating Scales (:CAARS). As previously communicated, the top-line data analysis was conducted on the Full Analysis Set (n=283), which includes all randomized subjects with at least one post-baseline efficacy assessment. Consistent with previously conducted studies, MDX was generally well tolerated.
- "We are exceedingly disappointed with these top-line results. In the coming weeks, the Company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and communicate our strategic plan to investors"
Sunday, January 15, 2017
Lamb Weston (LW) reported earnings Tue 10 Jan 2017 (b/o)
- Lamb Weston (LW) was spun-off by Conagra Foods (CAG) as an independent public company on November 10, 2016.
- Lamb Weston supplies frozen potato, sweet potato, appetizer and vegetable products to restaurants and retailers, with nearly $3 billion in annual sales.
** charts after earnings **
Lamb Weston beats by $0.07, beats on revs; guides FY17 EPS above consensus, raises sales outlook :
- Reports Q2 (Nov) earnings of $0.63 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.56; revenues rose 6.8% year/year to $790.7 mln vs the $772.1 mln two analyst estimate.
- Volume increased 4 percentage points as productivity programs and strong manufacturing plant performance stretched available capacity, allowing the Company to meet demand growth in both North America and international markets. Price/mix increased 3 percentage points due to pricing actions and favorable product and customer mix.
- Co issues upside guidance for FY17, sees EPS of $2.20-2.28, excluding non-recurring items, vs. $2.11 Capital IQ Consensus Estimate; sees net sales up mid-single digits vs. prior guidance for up low single digits. Co expects Adjusted EBITDA including unconsolidated joint ventures to grow at a mid-teens rate, up from a previous estimate of a high single digit increase, reflecting solid sales growth and savings from supply chain efficiencies, partially offset by lower contribution from equity method investment earnings. Potato costs are expected to remain essentially flat.
Lamb Weston President and CEO Tom Werner ringsa ceremonial bell after taking part in the company's IPO on the floor of the New York Stock Exchange (NYSE) in New York City, NY, U.S. November 15, 2016 (Courtesy: Reuters / Yahoo Finance)
Lamb Weston supplies frozen potato, sweet potato, appetizer and vegetable products to restaurants and retailers.
Saturday, January 7, 2017
Neiman Marcus withdraws IPO
Neiman Marcus' abandoned IPO underscores the challenges facing the high-end retailer, as the broader industry struggles under the weight of competitive pressure from off-price stores and online retailers such as Amazon.com Inc
Neiman Marcus declined to comment on the reasons for pulling the IPO.
Neiman Marcus, which also operates the Bergdorf Goodman and MyTheresa brands, was acquired by private equity firm Ares Management and Canada Pension Plan Investment Board three years ago for $6 billion.
The Dallas-based company filed to go public in August 2015, but it soon decided to put these plans on hold as a strong U.S. dollar hurt its store revenue in gateway tourist destinations such as New York, Las Vegas, Los Angeles and Hawaii.
Late 2015 through 2016 was a notably rocky period for IPOs, plagued by market jitters and volatility. Companies only raised $19 billion through public offerings last year, down 42 percent from $32 billion a year prior.
As skittish investors became more concerned with companies' earnings, some of the biggest victims of last year's IPO rut were private equity backed, highly indebted companies such as Neiman Marcus, which had been looking to use IPO proceeds to pay down debt.
As of late October, Neiman Marcus had about $4.9 billion in debt, including its asset-based revolving credit facility, much of which stemmed from its 2013 buyout. Last fall, lenders allowed it to push out a maturity on its revolving credit line to 2021, under certain conditions, from 2018, giving the company more time to boost sales to repay debt.
For the 12 months ending Sept. 26, Neiman Marcus reported $4.95 billion in sales, a decrease of 2.9 percent from the year prior. It also reported a net loss of $406 million, as compared to net earnings of $14.9 million a year earlier.
Wednesday, January 4, 2017
Hilton Grand Vacations (HGV) and Park Hotels & Resorts (PK) began trading on the NYSE on 4 Jan 2017
- Hilton (HLT) spinoffs
The transaction will create two new public companies: a real estate investment trust called Park Hotels & Resorts and the timeshare business Hilton Grand Vacations. Shares of both will begin trading Wednesday morning on the New York Stock Exchange. Park will use the ticker “PK” and Hilton Grand Vacations “HGV.”
Executives and guests of Hilton Grand Vacations (NYSE:HGV) visit the New York Stock Exchange (NYSE) to celebrate their spin-off from Hilton (NYSE:HLT). To mark the occasion President and Chief Executive Officer of Hilton Grand Vacations, Mark Wang, rings the Opening Bell. (Photo Credit: NYSE)
The move comes as Hilton takes on a much larger competitor in Marriott International Inc. (NASDAQ: MAR), which completed its merger with Starwood Hotels & Resorts in September. Hilton has about 300,000 rooms in its pipeline and a total of 789,000 rooms open. Marriott has 420,000 rooms in its pipeline and more than 1.1 million rooms open.
Park Hotels & Resorts is taking 69 properties off of Hilton’s hands, including the Hilton McLean Tysons Corner next to Hilton’s headquarters.
Subscribe to:
Posts (Atom)